Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer.
Saved in:
| Title: | Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer. |
|---|---|
| Authors: | Conca E; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Lorenzini D; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy., Minna E; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Agnelli L; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Duca M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Gentili M; Department of Pathology and Laboratory Medicine, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Bodini B; Department of Pathology and Laboratory Medicine, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Polignano M; Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Mantiero M; Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Damian S; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy., Devecchi A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Dagrada G; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Carminati R; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Ardore A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Barbetta F; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Da Chuna NB; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Guerrizio A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Busico A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Capone I; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Piccolo A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Tamborini E; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Perrone F; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Milione M; Department of Pathology and Laboratory Medicine, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Paolini B; Department of Pathology and Laboratory Medicine, Pathology Unit 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Vingiani A; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy., Raspagliesi F; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.; Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Braud F; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy., Pruneri G; Department of Diagnostic Innovation, Pathology Unit 2, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Aug 06; Vol. 15, pp. 1633410. Date of Electronic Publication: 2025 Aug 06 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
